13F Holdings
中文EN

ALXO ALX ONCOLOGY HOLDINGS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1810182 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY25.4%
TTM EPS YoY56.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-94.4%
ROA-67.9%
ROIC (approx.)-99.6%
Asset turnover—

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.08x
Current ratio8.04x
Interest coverage-67.78x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$0$0
R&D expense$77.00M$116.37M$141.79M$98.40M$60.17M
SG&A expense$23.85M$26.09M$28.48M$29.04M$23.39M
Operating income-$104.02M-$142.47M-$170.28M-$127.44M-$83.56M
Interest expense$1.60M$1.73M$1.56M$238,000$13,000
Pretax income-$101.69M-$134.85M-$160.81M-$123.42M-$83.48M
Income tax$0$0$0$64,000-$21,000
Net income-$101.69M-$134.85M-$160.81M-$123.48M-$83.46M
EBITDA-$103.31M-$141.59M-$169.44M-$127.09M-$83.50M
EPS (basic)-1.90-2.58-3.74-3.03-2.07
EPS (diluted)-1.90-2.58-3.74-3.03-2.07
Weighted avg. shares (diluted)53.66M52.17M42.99M40.70M40.31M
Balance sheet
Cash & equivalents$16.37M$17.63M$22.41M$48.89M$363.67M
Short-term investments$28.42M$110.19M$160.33M$217.38M—
Current assets$50.73M$134.35M$188.66M$270.97M$367.02M
PP&E, net$1.20M$2.90M$3.59M$3.89M$897,000
Total assets$59.05M$147.78M$242.55M$306.49M$380.18M
Current liabilities$24.55M$18.50M$36.00M$28.32M$15.29M
Short-term debt$5.22M$435,000$0$0—
Long-term debt$4.53M$9.47M$9.64M$9.39M—
Total debt$9.75M$9.90M$9.64M$9.39M—
Total liabilities$33.06M$34.16M$52.84M$43.02M$17.13M
Shareholders' equity$25.98M$113.62M$189.71M$263.46M$363.05M
Net debt-$6.62M-$7.73M-$12.77M-$39.50M—
Shares outstanding54.39M53.05M49.95M40.86M40.59M
Cash flow statement
Operating cash flow-$84.14M-$121.91M-$130.36M-$89.22M-$68.10M
Capital expenditure$212,000$447,000$1.27M$1.43M$666,000
Free cash flow-$84.35M-$122.36M-$131.64M-$90.65M-$68.77M
Investing cash flow$82.59M$86.26M$44.66M-$235.42M-$4.92M
Financing cash flow$362,000$30.82M$59.29M$9.86M$2.47M
Depreciation & amortization$706,000$872,000$836,000$342,000$51,000
Stock-based compensation$12.58M$27.09M$26.27M$23.84M$13.91M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.